← Back to Search

dose 1 for Cognitive Disorders

N/A
Recruiting
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 weeks

Summary

To evaluate the dose-response of relevant blood biomarkers to remote ischemic conditioning in patients with age-related cerebral white matter hyperintensities on MRI, in preparation for a subsequent larger efficacy trial.

Eligible Conditions
  • Cognitive Disorders
  • White matter hyperintensities

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
RBC deformability index
Secondary study objectives
inflammatory and anti-inflammatory Interleukins
tolerability

Trial Design

5Treatment groups
Active Control
Placebo Group
Group I: dose 1Active Control1 Intervention
BP cuff bilateral arm compression to 50 mmHg above systolic BP for 2.5 minutes on/off for 4 cycles every other day.
Group II: dose 3Active Control1 Intervention
BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off once daily.
Group III: dose 2Active Control1 Intervention
BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off for 4 cycles every other day.
Group IV: dose 4Active Control1 Intervention
BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off twice daily.
Group V: shamPlacebo Group1 Intervention
BP cuff bilateral arm compression to 50 mmHg.

Find a Location

Who is running the clinical trial?

Georgia Rehabilitation InstituteUNKNOWN
Augusta UniversityLead Sponsor
215 Previous Clinical Trials
85,650 Total Patients Enrolled
Carol Smith, RNStudy DirectorWellstar MCG Health
~8 spots leftby Nov 2025